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Abstract
Background: A randomized controlled trial ‘Money for Medication’(M4M) was conducted in which patients were
offered financial incentives for taking antipsychotic depot medication. This study assessed the attitudes and ethical
considerations of patients and clinicians who participated in this trial.
Methods: Three mental healthcare institutions in secondary psychiatric care in the Netherlands participated in this
study. Patients (n = 169), 18–65 years, diagnosed with schizophrenia, schizoaffective disorder or another psychotic
disorder who had been prescribed antipsychotic depot medication, were randomly assigned to receive 12 months
of either treatment as usual plus a financial reward for each depot of medication received (intervention group) or
treatment as usual alone (control group). Structured questionnaires were administered after the 12-month
intervention period. Data were available for 133 patients (69 control and 64 intervention) and for 97 clinicians.
Results: Patients (88%) and clinicians (81%) indicated that financial incentives were a good approach to improve
medication adherence. Ethical concerns were categorized according to the four-principles approach (autonomy,
beneficence, non-maleficence, and justice). Patients and clinicians alike mentioned various advantages of M4M in
clinical practice, such as increased medication adherence and improved illness insight; but also disadvantages such
as reduced intrinsic motivation, loss of autonomy and feelings of dependence.
Conclusions: Overall, patients evaluated financial incentives as an effective method of improving medication
adherence and were willing to accept this reward during clinical treatment. Clinicians were also positive about the
use of this intervention in daily practice. Ethical concerns are discussed in terms of patient autonomy, beneficence,
non-maleficence and justice. We conclude that this intervention is ethically acceptable under certain conditions,
and that further research is necessary to clarify issues of benefit, motivation and the preferred size and duration of
the incentive.
Trial registration: Nederlands Trial Register, number NTR2350.
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Background
Patients with psychotic disorders often have problems
adhering to their prescribed antipsychotic medication
[1], making it difficult to control their psychiatric symp-
toms. Non-adherence has also been associated with an
increased risk of hospital admissions, suicide attempts,
violence, self-harm, substance use and treatment costs
[2–4]. Unfortunately, interventions to improve adher-
ence such as psychoeducation or adherence therapy
have not been consistently successful for patients with
schizophrenia [5].
Although providing financial incentives for taking anti-
psychotic depot medication is an effective intervention
for improving adherence [6–9], clinicians and healthcare
workers have several ethical reasons for criticising the
use of financial incentives among patients with severe
mental illnesses. For example, 76% managers of assertive
outreach teams surveyed in England stated one or more
ethical reason for refusing to provide this intervention
[10]. First, patients may feel bribed or coerced into tak-
ing their medication – because they need income, for
example [11]. Second, the therapeutic relationship might
be damaged if patients receive financial incentives,
possibly undermining voluntary medication adherence
[6]. Finally, if illness or medication impairs patients’
decision-making capacities, it is unreasonable to expect
them to make informed decisions about their treatment
process, including the incentive [12]. This raises ethical
concerns about respecting patient autonomy.
Offering financial incentives may also have negative
consequences on patients’ intrinsic motivation for treat-
ment [13–15]. If financial incentives are offered only to
non-adherent patients and are eventually removed, pa-
tients could refuse all medication (‘crowding out effect’)
[16] or may deliberately become non-adherent in order
to receive financial incentives again [17]. Similarly, many
patients with severe mental illnesses are vulnerable or
have impaired decision-making capacity, which some-
times gives clinicians the feeling they are ‘buying’ their
patients.
A focus group study by Priebe and colleagues [18]
explored the attitudes of different stakeholders (i.e. pa-
tients, psychiatrists, nurses, social workers, psychologists
and multidisciplinary teams) towards the ethical accept-
ability of financial incentives. They identified several
themes – including coercion, effectiveness and perverse
incentive – that dominated the discussion. Each stake-
holder group tended to indicate the same discussion
threads. However, few patients (n = 27) participated in
this study, and neither patients nor clinicians had any
actual experience of using financial incentives.
As prior research has thus focused on clinicians’ be-
liefs about applying this intervention [19], greater atten-
tion should be paid to evaluating the ethical concerns
and considerations of patients who have had practical
experience of financial incentives. We therefore report
on patients and clinicians who participated in Money for
Medication, a randomized controlled trial [9] in which
patients were offered financial incentives for taking anti-
psychotic depot medication for a 12-month intervention
period. The opinions of patients and clinicians on this
intervention were organized on the basis of the four-
principles approach of Beauchamp and Childress [20].
This pragmatic approach [21] was used to categorize
ethical arguments into one of the following ethical prin-
ciples: autonomy (the right of competent patients to
make their own decisions, and the obligation to respect
the decision-making capacities of autonomous persons);
beneficence (the obligation to provide benefits and to
balance benefits against risks); non-maleficence (the ob-
ligation to avoid causing harm); and justice (the obliga-
tion of fairness in the distribution of benefits and risks).
Methods
Design
Data were collected in the context of Money for Medica-
tion (M4M), a multicentre, open-label, parallel-group, ran-
domized controlled trial [9]. The study was approved by
the accredited Dutch Medical Ethical Trial Committee at
Erasmus University Medical Center (NL31406.097.10; file
number P13.258) and registered with the Netherlands Trial
Register (NTR2350).
Participants
Participants were included at three mental health-care
institutions in secondary psychiatric care services in the
Netherlands: the Dual Diagnosis Center (CDP) Palier,
Parnassia, and BavoEuropoort. Primarily these organisa-
tions treat patients with psychotic and other severe
mental disorders (often with comorbid substance use).
In general, at the start of the study, these patients
received voluntary treatment and are motivated by the
clinicians to accept their medication. Involuntary out-
patient treatment was not an in- or exclusion criterion
for participation in the study. Eligible patients were aged
between 18 and 65 years, had a psychotic disorder (such
as schizophrenia, schizoaffective disorder or another
psychotic disorder) classified by psychiatrists using the
DSM-IV; had been prescribed antipsychotic depot medi-
cation or had an indication to start using depot medica-
tion; and were participating in outpatient treatment. All
patients had given written informed consent before the
baseline interview was conducted. Exclusion criteria
were: inability to participate due to cognitive impair-
ments (as determined by the clinicians on the basis of
their clinical judgement or stated in the patients’ record)
and/or insufficient understanding of Dutch (observation
of research assistants during interviews). Patients who
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initially met the inclusion criteria were informed about
the study by their clinicians and were asked to partici-
pate. If a patient declined to participate, this decision
was registered anonymously to allow assessment of
selection bias.
Procedure and data collection
In total, 879 patients from the mental healthcare teams
were assessed for eligibility; 710 patients were excluded
because:(1) they had no prescription or indication for
antipsychotic depot medication (n = 460), (2) did not
react to requests for participation in the trial (n = 101),
(3) refused participation (n = 28), (4) or various other
reasons (n = 121), including being admitted to a
hospital, moving house to a different city, transfer to
another treatment team, imprisonment, or insufficient
information to be contacted. Between May 21, 2010 and
October 15, 2014, 169 patients were randomly allocated
to 12 months of experimental treatment (M4M) or to
12 months of treatment as usual (TAU; control condi-
tion). Randomisation was stratified by treatment site and
suspected prognostic factors: sex, comorbid substance-
use disorder (absent vs present), and compliance with
antipsychotic medication in the 4 months before base-
line (<50% vs ≥50%). During the intervention period, no
patients refused participation due to the content of the
study. TAU consisted of outpatient treatment provided by
community mental-health teams and flexible assertive-
community-treatment teams.
Patients in the intervention group (M4M) received
treatment as usual, plus a financial reward each time they
received their prescribed depot of antipsychotic medica-
tion during the 12-month experimental study phase. The
maximum amount they received was €30 per month. The
rewards were paid out by the patients’ treating nurses as
soon as the patient had received the injection or had
swallowed the penfluridol. The methods and results of the
study have been described in Noordraven et al. [9].
Assessment and questionnaire
After the 12-month intervention period, patients’ and clini-
cians’ attitudes and opinions were assessed using a short
questionnaire constructed for the study. The first question
asked whether this intervention was a ‘good idea’ or a ‘bad
idea’. Next, two open-ended questions asked about the ad-
vantages and disadvantages of using financial incentives.
Nineteen statements then addressed ethical considerations
on the consequences of M4M on topics such as the thera-
peutic relationship, intrinsic motivation, inequality between
patients, and patient vulnerability (Additional file 1 shows
our complete questionnaire). Items were scored on a 5-
point scale (1 = strongly disagree, 5 = strongly agree) and
dichotomized into ‘disagree’ (scores 1, 2, 3) and ‘agree’
(scores 4 and 5). To assess the effect of alternative
breakpoints, sensitivity analyses were performed; no rele-
vant differences were found. All interviews were conducted
by extensively trained research assistants (Master’s-level
psychologists).
To explore the different components of ethical con-
cerns, each statement was categorized post-hoc into one
of the four ethical principles (Table 1): ‘autonomy’ (items
4, 7, 18; expressed in statements such as ‘if they receive
money for their depot medication, patients will feel forced
to accept their depots’ and ‘it is not permissible to buy pa-
tients by giving them money to take their medication’);
‘beneficence’ (items 1, 2, 3, 5, 6, 11, 15, 19; expressed in
statements such as ‘patients will accept their depots more
often if they receive money’ and ‘money for depots improves
patients’ motivation to use depot medication’); ‘non-malefi-
cence’ (items 9, 12, 13, 14; expressed in statements such
as ‘Money for depots is harmful to the therapeutic relation-
ship’ and ‘if someone receives money for his depot, he won’t
gain insight into his problems’); and ‘justice’ (item 8,
expressed in a single statement: ‘jealousy will arise if some
patients receive money for their depots and others do not’).
Statements that did not fit the description of these princi-
ples were labelled as ‘other considerations’ (items 16, 17).
We also described the commonest advantages and
disadvantages named spontaneously by patients and
clinicians in response to the open-ended questions. Using
descriptive statistics, we identified differences between pa-
tients and clinicians, and explored the differences between
patients who had actually received the intervention (M4M
group) and those who had not (TAU group). All analyses
were performed using SPSS version 21.0.
Results
After the 12-month intervention period, interview data
were available for 133 patients and 97 clinicians (Table 2).
Patients lost to follow-up showed no significant differ-
ences relative to patients who had outcome data after
12 months, and were distributed equally across conditions
(17 intervention and 19 control). Because of (repeated)
non-attendance, we were unable to conduct follow-up in-
terviews for these patients. However, they did not actively
withdrew their consent to participate in our study, nor did
they report any (ethical) concerns as reason for non-
attendance. Overall, 88% of the patients and 81% of the
clinicians reported that the M4M project was a good idea.
These percentages were similar between patients from the
intervention group (92%) and the control group (84%).
Patients versus clinicians
Autonomy
Around 33% of the patients and clinicians reported
that if patients were offered money, they would feel
dependent, pressured or coerced to accept their anti-
psychotic depots.
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Beneficence
Patients (79%) and clinicians (72%) believed that patients
would be more adherent to their antipsychotic depot
medication if financial incentives were used. Similarly, a
majority of patients (72%) and clinicians (82%) agreed
that ‘money for depots would improve the motivation to
use depot medication’. However, only 58% of patients
and 42% of clinicians agreed with the statement that
‘money for depots is beneficial for patients wellbeing’.
Non-maleficence
Although few patients (23%) agreed with the idea that ‘if
someone receives money for his depot, he won’t gain insight
into his problems’, more clinicians (35%) were worried about
this negative consequence. While clinicians (71%) also
agreed with the statement that financial incentives would
provoke patients into follow treatment less for themselves
but more for the money, this opinion was shared by fewer
patients (38%). A majority of the patients (84%) and clini-
cians (84%) stated that they did not expect the therapeutic
relationship to suffer from the use of monetary rewards.
Justice
This statement referred to the obligation to treat like
cases alike. A majority of the patients (62%) and clini-
cians (71%) believed that jealousy would occur if
some patients received money for their depots but
others did not.
Table 2 Characteristics of patients and clinicians
Variable Patients (n = 133) Clinicians (n = 97)
Age, mean (SD) years 40.3 (9.4) 41.5 (12.5)
Gender, N (%)
Male 99 (74) 35 (37)
Duration of illness
mean (SD), years
12.1 (8.3) -
Diagnosis, N (%)
- Schizophrenia paranoid type 75 (56.4) -
- Schizoaffective disorder 15 (11.3) -
- Psychotic disorder NOS 14 (10.5) -
- Schizophrenia disorganized
type
9 (6.8) -
- Other schizophrenic disorder 20 (15.0) -
Working experience, mean
(SD), years
- 14.4 (11.4)
Job description, N (%)
- Psychiatrist - 9 (9)
- Psychologist - 11 (11)
- Social worker - 15 (15)
- Social psychiatric nurse - 20 (21)
- Nurse - 25 (26)
- Intern - 9 (9)
- Other - 8 (8)
Table 1 Patients’ and clinicians’ agreement with ethical aspects of the Money for Medication intervention to improve medication
adherence
Ethical concern Statement Patients (N = 133) Clinicians (N = 97)
‘Patients will feel dependent if they receive money for their depots’ 33% (44) 31% (30)
Autonomy ‘If they receive money for their depot medication, patients will feel forced to
accept their depots’
36% (47) 27% (26)
‘It is not permissible to buy patients by giving them money to take their medication’ 21% (27) 16% (15)
Beneficence ‘To give money for depots is good’
‘Giving money for depots emphasizes the things that are going well’
‘Money could just be the right push to accept your depot’
‘Money for depots improves patients’ motivation to use depot medication’
‘Money for depots will work in daily practice’
‘Money for depots helps to get into a positive flow’
‘Patients will accept their depots more often when they receive money’
‘Money for depots is beneficial for patients wellbeing’
‘If patients receive money for their depot they will accept it more often’
68% (91)
51% (66)
72% (96)
72% (95)
67% (89)
62% (81)
79% (103)
58% (76)
75% (98)
47% (46)
33% (32)
88% (85)
82% (80)
53% (51)
61% (59)
72% (70)
42% (41)
79% (77)
‘If someone receives money for his depot, he won’t gain insight into his problems’ 23% (30) 35% (34)
‘Money for depots is harmful to the therapeutic relationship’ 16% (21) 16% (16)
Non-maleficence ‘If patients no longer receive money for their depots they will stop to accept
their depots’
‘Money for depots will provoke patients to follow their treatment less for themselves
but more for the money’
36% (47)
38% (49)
37% (45)
71% (69)
Justice ‘Jealousy will arise if some patients receive money for their depots and others
do not’
62% (82) 71% (69)
Other ‘Giving money for depots is ethically acceptable’ 49% (64) 34% (33)
‘It is good to reward good behavior with money’ 76% (99) 38% (37)
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Other considerations
While most patients (76%) agreed with the statement
that it would be good to reward good behaviour with
money, fewer clinicians (38%) did so. Nearly half the
patients (49%) agreed that giving money for depots was
ethically acceptable, an opinion shared by a third of
clinicians (34%).
Between patients: Experimental group versus control group
Overall, the ratings on the questionnaire items did not
differ significantly between intervention and control pa-
tients. Intervention patients rated M4M somewhat more
positively than control patients on only two items:
‘money for depots will work in daily practice’ (77%
vs. 59%) and it is ‘ethically acceptable to give money
for depots’ (57% vs. 41%).
Spontaneously reported advantages and disadvantages
Eighty-two patients and 87 clinicians spontaneously
reported five advantages of using financial incentives: in-
creased compliance (15 patients (18%) vs. 40 clinicians
(46%)); increased motivation for treatment (15 patients
(18%) vs. 32 clinicians (37%)); more money to spend (34
patients (41%) vs. 5 clinicians (6%)); more time to talk
with patients (11 patients (13%) vs. 1 clinician (1%)); and
improved illness insight (7 patients (9%) vs. 9 clinicians
(10%)). Similarly, 27 patients and 74 clinicians named
five potential disadvantages: becoming dependent and re-
fusing all depots when financial incentives were no longer
offered (7 patients (26%) vs. 24 clinicians (32%)); becom-
ing externally motivated for treatment (7 patients (26%)
vs. 23 clinicians (31%)); the unfairness of some patients
not receiving financial incentives (10 patients (37%) vs. 6
clinicians (8%)); the possibility that patients would not
gain illness insight (1 patient (4%) vs. 12 clinicians
(16%)); and the risk that patients would use the money to
buy drugs (2 patient (7%) vs. 8 clinicians (11%)).
Discussion
This 12-month randomized controlled trial explored
patients’ and clinicians’ ethical concerns regarding the
use of financial incentives to improve adherence to anti-
psychotic depot medication. In general, patients viewed
such incentives as an effective method of improving
their adherence, and were willing to accept them during
clinical treatment. Clinicians were also positive about
using this intervention in clinical practice, and had
ethical concerns that were similar to those identified by
their patients.
However, even though they reported that offering
financial incentives was a good idea, only a minority of
the clinicians and about half of the patients believed this
intervention to be ethically acceptable. These answers
show the complex and possible ambivalent attitudes
about using financial incentives. Patients might be prag-
matic and state that they think of this intervention as a
‘good idea’; believing it will be efficient in daily practice,
for example. At the same time, independent from this
practical oriented vision, they might believe this inter-
vention is not an ethical practice. Although these results
may seem contradictory, they may be two sides of the
same coin. An example to illustrate this point is the clas-
sic trolley thought-experiment [22]: a dilemma between
killing 1 person in order to save 5. Most people would
reason from a rational point of view this would be a
valid choice to make (‘good idea’), while at the same
time, still believing that it is overall unethical to end an-
other persons’ life (‘ethical acceptability’). In this study,
patients and clinicians believed that monetary payments
would improve medication adherence, even though both
groups were worried that jealousy would occur if some
patients received monetary payments and others did not.
Ethical concerns were grouped on the basis of the four-
principles approach in terms of patient autonomy,
beneficence, non-maleficence and justice.
Autonomy
From a consequentialist standpoint, a given intervention
would be legitimate if the outcomes were beneficial. In
this case, financial incentives increased medication ad-
herence, which was the primary aim of the study [9].
However, we would argue that it is not sufficient to
focus only on the outcomes of an intervention: the act
of giving financial incentives itself should also be evalu-
ated independently of its consequences. Regardless of
the outcomes, ‘bribing’ or coercing patients into using
medication would be ethically problematic. To respect
patients’ autonomy, one should therefore evaluate the
amount of money being offered [23]. If, for example, pa-
tients were offered €1000 per depot taken (whether
weekly or monthly), they would likely cross their per-
sonal boundaries more easily, and might feel coerced
into accepting their medication. Particularly among
patients with a psychosis, who are often in need of
financial support, the payment should not be that high
to make them feel forced to accept medication [24].
While some 30% of the patients in this study believed
that patients would feel forced or dependent if offered
monetary payments, we would argue that it is legitimate
to offer incentives that make patients feel slightly pres-
sured –but not coerced or manipulated- to take their
depots [25]. We also believe that outright coercion was
not involved in our study, since no consequences were
attached to rejection of the medication and financial
reward: patients who rejected depots were not forced to
take their medication, nor were they admitted involun-
tarily. In practice, the size of the payment should be
chosen in a way that always leaves patients with a fair
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opportunity to say no, if they really do not want to do
something. To respect patient autonomy and prevent
coercion, the use of incentives should not be considered
before carefully weighing the size of the payment in rela-
tion to the specific patient population, and before consid-
ering whether the incentive being offered is unconditional.
Beneficence
A majority of the patients and clinicians were convinced
that offering financial incentives would increase adher-
ence to antipsychotic depot medication. However, only
around 50% of them believed this intervention would
also benefit patients’ wellbeing. The fact that the in-
creased medication adherence in this study did not lead
to improved clinical outcomes, such as better quality of
life or fewer hospital admissions [9], shows a complex
association between adherence and patients’ wellbeing.
This makes it difficult to conclude whether this inter-
vention is truly beneficial. Offering financial incentives
did benefit the number of accepted depots – which was
our primary aim – and patients and clinicians alike
acknowledged that patients’ motivation to accept their
medication had improved.
Although medication non-adherence has been shown
to be associated with various negative clinical outcomes,
such as increased risk of hospital admissions, suicide at-
tempts, violence or substance abuse, our study did not
improve clinical outcomes. We would nonetheless argue
in favour of using monetary payments: they are effective
for improving medication adherence and there are vari-
ous reasons why we did not find improvements in clin-
ical outcomes. While these reasons have been discussed
in depth elsewhere [9], they should be summarized
briefly here. First, our overall study was designed pri-
marily to improve adherence and to study the effective-
ness of using financial rewards. At 12 months, the study
may have been too short to detect any improvements in
clinical symptoms, especially among chronically ill pa-
tients with a mean illness duration of about 12 years.
But we should also note that clinical outcome measures
did not get worse during the intervention period, and
there were no indications that M4M negatively affected
patient autonomy or therapeutic relationships. There-
fore, we believe that it is ethically acceptable to use
M4M in clinical practice, even though we found no
improvements on clinical outcomes.
Non-maleficence
An important concern in previous studies is that finan-
cial incentives would undermine the therapeutic rela-
tionship between patients and clinicians. Clinicians
might feel reluctant to offer payments if these could
damage or disrupt the relationships with their patients,
which are often built with great difficulty and over long
periods of time. After the 12-month intervention period,
however, patients and clinicians did not report any indi-
cations that the therapeutic relationship had suffered
from the use of monetary rewards. In addition, patients
in the M4M condition did not report more side effects
of medication, nor did they use more alcohol or illicit
drugs than patients in the control group.
Another ethical concern was the concept of ‘motiv-
ation’. Clinicians believed that patients would follow
treatment less for themselves and more for the money.
They are worried that externally motivated patients will
stop to take their medication when incentives are no
longer given, since it has been shown that initial positive
behaviour changes cannot be sustained after withdrawal
of external rewards [26]. Patients, however, disagreed
with these concerns. Furthermore, we found that during
the 6 month follow-up period, the intervention group
still accepted more depots than patients from the con-
trol group. This shows that financial incentives can be
discontinued without the danger of patients becoming
completely non-adherent or less adherent than before
receiving financial payments.
Justice
While some patients received money and other patients
did not, a majority of patients and clinicians reported
that jealousy could occur. If this intervention were used
only with non-adherent patients, this could lead adher-
ent patients to become non-adherent on purpose, or to
complain about unequal treatment. Clinicians also sus-
pected that patients might reject their medication if pay-
ments were no longer offered, while patients themselves
did not expect this to happen. For reasons of justice and
to overcome this problem of inequality, we therefore
recommend that all patients are offered payments for
accepting their depot medication [23] – as in our
study – without making distinctions based on previous
levels of adherence.
Strengths and limitations
Our study is one of the first to collect empirical data on
patients’ and clinicians’ opinions after patients have re-
ceived financial incentives for accepting antipsychotic
depot medication. This is important: the opinions of pa-
tients with psychotic disorders are often overlooked, but
are crucial if we wish to improve treatment. Another
advantage of our study is that patients and clinicians all
experienced the intervention in daily practice. Their opin-
ions were thus based in practice much more than if the
intervention had merely been discussed hypothetically.
A limitation of the study is that our questionnaire was
not constructed on the basis of a previously defined
theoretical model: instead, we retrospectively categorized
each statement into one of the four main ethical
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principles and explored patients’ and clinicians’ different
views on the intervention. Another limitation is that se-
lection bias may have occurred with respect to the total
population of patients on depot medication. Patients
who participated might have been biased towards a more
positive attitude on using financial incentives, simply be-
cause all patients wanted to participate in this study, and
showed up for appointments to conduct our interviews.
However, we found no differences between patients who
actually received financial incentives (M4M group) and
those who did not (TAU group).
Conclusions
In clinical practice, patients and clinicians were positive
about the use of financial payments to improve adher-
ence to antipsychotic depot medication. Importantly, the
fear that financial incentives would harm the therapeutic
relationship was not confirmed. At the same time, how-
ever, more than half of the patients and clinicians re-
ported to have ethical concerns (e.g. jealousy or reduced
illness insight). Therefore, we consider the use of monet-
ary incentives to take anti-psychotic depot medication to
be ethically acceptable on four conditions: the amount
offered should be moderate, the offer should be uncon-
ditional (i.e. there are no consequences if the patient
refuses); the incentives should be made available to all
patients; and a monitoring system should be in place to
track changes in patients’ health and/or well-being.
However, it still remains unclear to what extent this
type of intervention affects internal and external motiv-
ation for treatment, and for how long monetary pay-
ments should be offered. Our results showed that when
financial payments were no longer offered, most patients
from the intervention group continued to have improved
adherence rates, whereas others relapsed. This indicates
that for most patients, temporary incentives might be
sufficient to improve their motivation for medication in-
take over a longer period of time, while for others, con-
tinuous payments might be more suitable to maintain
higher adherence rates. Longer follow-up periods are
needed to examine whether sustained improved adher-
ence might be associated with better clinical outcomes.
For practical purposes, however, and to prevent difficul-
ties (e.g. jealousy, inequality between patients, risks of
becoming non-adherent on purpose in order to receive
incentives), we recommend offering financial incentives
to all patients without making distinctions.
Future research should also examine the optimal level
of incentives; if incentives are too substantial, this could
increase the likelihood of bribing patients into doing
something they might not want, instead of offering them
an independent choice. Also, higher incentives might
harm the therapeutic relationship. The incentive in the
present study was pragmatically chosen based on
promising results from an earlier pilot study and another
RCT [8, 27]. In addition, and from a more practical per-
spective, almost all patients received social welfare,
which they might lose when receiving a substantial
source of extra income (e.g. ≥€30). For these reasons, we
believe the amount of 30 euro is relatively adequate, but
this needs to be addressed in future studies.
To conclude, our study suggests that, under certain
conditions, money for medication is an ethically accept-
able intervention for improving medication adherence.
Issues of benefit, motivation and the size and duration
of the incentive should be clarified in further research.
Additional file
Additional file 1: ‘Appendix A. Money for medication questionnaire’.
This file shows the original questionnaire that was used in this study,
containing 2 open-ended questions and 19 statements which were
scored on a 5-point scale (1 = strongly disagree, 5 = strongly agree).
(DOCX 102 kb)
Abbreviations
M4M: Money for Medication (intervention group); TAU: Control group
Acknowledgements
We thank the patients, research assistants, clinicians, and health-care facilities
that participated in this study.
Funding
This study was funded by the Dual Diagnosis Center (CDP) Palier. The funder
of the study had no role in study design, data collection, data analysis, data
interpretation, or writing the report. The corresponding author had full
access to all the data in the study and had final responsibility for the
decision to submit for publication.
Availability of data and materials
Data and subsequent syntax records used for this article are available from
the corresponding author on reasonable request.
Authors’ contributions
ELN, MHNS, AIW, PB, and CLM conceived and designed the study. ELN
acquired the data and monitored the process. ELN, AIW, PB, MHNS, and CLM
had full access to all the data (statistical reports, analyses, and tables) in the
study and take responsibility for the integrity of the data and the accuracy of
the data analysis. All authors were involved in the analysis. ELN drafted the
manuscript and MHNS, AIW, PB and CLM critically revised it for important
intellectual content. CLM is the guarantor of the study. All authors read and
approved the final manuscript.
Ethics approval and consent to participate
The consent procedures and study protocol were approved by the
accredited Dutch Medical Ethical Trial Committee (registration number
NL31406.097.10, file number P13.258) of the Erasmus University Medical
Center. All patients provided written informed consent before participating
in this study.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Noordraven et al. BMC Psychiatry  (2017) 17:313 Page 7 of 8
Author details
1Dual Diagnosis Center (CDP) Palier, Parnassia Psychiatric Institute, 2552 KS
The Hague, The Netherlands. 2Department of Psychiatry, Erasmus University
Medical Center, Epidemiological and Social Psychiatric Research Institute,
3015CE Rotterdam, The Netherlands. 3Bavo-Europoort Mental Health Care,
3066 TA Rotterdam, The Netherlands. 4Parnassia Addiction Research Centre
(PARC), Brijder Addiction Treatment, Parnassia Psychiatric Institute, 2553 RJ
The Hague, The Netherlands.
Received: 22 May 2017 Accepted: 23 August 2017
References
1. Valenstein M, Ganoczy D, McCarthy JF, Myra Kim H, Lee TA, Blow FC.
Antipsychotic adherence over time among patients receiving treatment for
schizophrenia: a retrospective review. J Clin Psychiatry. 2006;67:1542–50.
2. Ascher-svanum H, Ph D, Zhu B, Faries D, Lacro JP, Pharm D, et al. A
prospective study of risk factors for nonadherence with antipsychotic
medication in the treatment of schizophrenia. J Clin Psychiatry.
2006;67:1114–23.
3. Ward A, Ishak K, Proskorovsky I, Caro J. Compliance with refilling
prescriptions for atypical antipsychotic agents and its association with the
risks for hospitalization, suicide, and death in patients with schizophrenia in
Quebec and Saskatchewan: a retrospective database study. Clin Ther. 2006;
28:1912–21. doi:10.1016/j.clinthera.2006.11.002.
4. Novick D, Haro JM, Suarez D, Perez V, Dittmann RW, Haddad PM. Predictors
and clinical consequences of non-adherence with antipsychotic medication
in the outpatient treatment of schizophrenia. Psychiatry Res. 2010;176:109–13.
doi:10.1016/j.psychres.2009.05.004.
5. Gray R, Bressington D, Ivanecka A, Hardy S, Jones M, Schulz M, et al. Is
adherence therapy an effective adjunct treatment for patients with
schizophrenia spectrum disorders? A systematic review and meta-analysis.
BMC Psychiatry. 2016;16:90. doi:10.1186/s12888-016-0801-1.
6. Claassen D, Fakhoury W, Ford R, Priebe S. Money for medication: financial
incentives to improve medication adherence in assertive outreach. Psychiatr
Bull. 2007;31:4–7.
7. Staring ABP, Van der Gaag M, Mulder CL. Schizophrenia and antipsychotic
medication - better adherence, better outcomes? Schizophr Res. 2013;151:
296–7. doi:10.1016/j.schres.2013.10.035.
8. Priebe S, Yeeles K, Bremner S, Lauber C, Eldridge S, Ashby D, et al.
Effectiveness of financial incentives to improve adherence to maintenance
treatment with antipsychotics : cluster randomised controlled trial. BMJ.
2013;345:f5847. doi:10.1136/bmj.f5847.
9. Noordraven EL, Wierdsma AI, Blanken P, Bloemendaal AFT, Staring ABP,
Mulder CL. Financial incentives for improving adherence to maintenance
treatment in patients with psychotic disorders (money for medication): a
multicentre, open-label, randomised controlled trial. Lancet Psychiatry.
2017;4:199–207. doi:10.1016/S2215-0366(17)30045-7.
10. Claassen D. Financial incentives for antipsychotic depot medication: ethical
issues. J Med Ethics. 2007;33:189–93. doi:10.1136/jme.2006.016188.
11. Shaw J. Is it acceptable for people to be paid to adhere to medication?
BMJ. 2007;335:232. doi:10.1136/bmj.39286.399514.BE.
12. Cairns R, Maddock C, Buchanan A, David AS, Hayward P, Richardson G, et al.
Prevalence and predictors of mental capacity in psychiatric inpatients. Br J
Psychiatry. 2005;187:379–85. doi:10.1176/appi.psy.48.4.309.
13. Promberger M, Marteau TM. When do financial incentives reduce intrinsic
motivation? Comparing behaviors studied in psychological and economic
literatures. Health Psychol. 2013;32:950–7. doi:10.1037/a0032727.
14. Kendall T. Paying patients with psychosis to improve adherence. Br Med J.
2013;347:1–2. doi:10.1136/bmj.f5782.
15. Brown RCH. Social values and the corruption argument against financial
incentives for healthy behaviour. J Med Ethics. 2017:140–4. doi:10.1136/
medethics-2016-103372.
16. Burton A, Marougka S, Priebe S. Do nancial incentives increase treatment
adherence in people with severe mental illness? A systematic review.
Epidemiol Psychiatr Sci. 2010;19:233–42. doi:10.1017/S1121189X00001160.
17. Szmukler G. Financial incentives for patients in the treatment of psychosis. J
Med Ethics. 2009;35:224–8. doi:10.1136/jme.2008.027151.
18. Priebe S, Sinclair J, Burton A, Marougka S, Larsen J, Firn M, et al.
Acceptability of offering financial incentives to achieve medication
adherence in patients with severe mental illness: a focus group study. J
Med Ethics. 2010;36:463–8. doi:10.1136/jme.2009.035071.
19. Highton-Williamson E, Barnicot K, Kareem T, Priebe S. Offering financial
incentives to increase adherence to antipsychotic medication: the
clinician experience. J Clin Psychopharmacol. 2015;35:120–7.
doi:10.1097/JCP.0000000000000276.
20. Beauchamp TL, Childress JF. Principles of biomedical ethics. 7th ed. New
York, Oxford: Oxford University Press; 2012.
21. Bloch S, Green SA. “an ethical framework for psychiatry”: comment. Br J
Psychiatry. 2006;189:7–13. doi:10.1192/bjp.188.1.7.
22. Foot P. The problem of abortion and the doctrine of the double effect.
Oxford Rev. 1967:5–15. doi:10.1093/0199252866.001.0001.
23. Burns T. Is it acceptable for people to be paid to adhere to medication?
BMJ. 2007;335:233. doi:10.1136/bmj.39286.422639.BE.
24. Szmukler G, Appelbaum PS. Treatment pressures, coercion and
compulsion in mental health care. J Ment Health. 2008;17:229–31.
doi:10.1080/09638230802156731.
25. Nelson RM, Beauchamp T, Miller V a, Reynolds W, Ittenbach RF, Luce
MF. The concept of voluntary consent. Am J Bioeth 2011;11:6–16.
doi:10.1080/15265161.2011.583318.
26. Dickerson FB, Tenhula WN, Green-Paden LD. The token economy for
schizophrenia: review of the literature and recommendations for future
research. Schizophr Res. 2005;75:405–16. doi:10.1016/j.schres.2004.08.026.
27. Staring ABP, Mulder CL, Priebe S. Financial incentives to improve adherence
to medication in five patients with schizophrenia in the Netherlands.
Psychopharmacol Bull. 2010;43:5–10.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Noordraven et al. BMC Psychiatry  (2017) 17:313 Page 8 of 8
